Thus, further studies will necessary to verify the role of NLRP3 in the pathogenesis of CI-AKI and highlight its clinical value through adding NLRP3 pharmacological inhibitor, for example, Arglabin29, to the in vivo researches. This evidence concerns the gene NLRP3 and acute kidney injury.